首页> 外文期刊>Geriatric Care >Iron deficiency and iron deficiency anaemia in elderly patients with chronic heart failure
【24h】

Iron deficiency and iron deficiency anaemia in elderly patients with chronic heart failure

机译:老年慢性心力衰竭患者的铁缺乏和铁缺乏性贫血

获取原文
       

摘要

Iron deficiency affects up to 50% of heart failure patients, and is associated with poor quality of life, impaired exercise tolerance, and mortality independent of haematopoietic effects in this patient population. Iron absorption from oral iron preparations is generally poor, with slow and often inefficient iron repletion; moreover, up to 60% of patients experience gastrointestinal side effects. These problems may be exacerbated in heart failure due to decreased gastrointestinal absorption and poor compliance due to pill burden. Intravenous (i.v.) iron sucrose has consistently been shown to improve exercise capacity, cardiac function, symptom severity, and quality of life. Similar findings were observed recently for i.v. ferric carboxymaltose in patients with systolic heart failure and impaired left ventricular ejection fraction. I.v. iron therapy may be better tolerated than oral iron. Routine diagnosis and management of iron deficiency in patients with symptomatic heart failure regardless of anaemia status is advisable, and, based on current evidence, prompt intervention using i.v. iron therapy should now be considered.
机译:铁缺乏症影响多达50%的心力衰竭患者,并与生活质量差,运动耐力受损和死亡率无关,而该患者人群中的铁缺乏与造血作用有关。口服铁制剂中的铁吸收通常较差,补铁缓慢且常常效率低下。此外,多达60%的患者会出现胃肠道副作用。由于胃肠道吸收减少以及药丸负担导致依从性差,这些问题在心力衰竭中可能会加剧。静脉内(i.v.)蔗糖铁一直被证明可以改善运动能力,心脏功能,症状严重程度和生活质量。最近在i.v.收缩性心力衰竭和左心室射血分数受损的患者中的铁羧甲基麦芽糖。 I.v.铁疗法可能比口服铁剂耐受性更好。不论贫血状况如何,对有症状心力衰竭患者的铁缺乏症进行常规诊断和治疗都是可取的,并且,根据目前的证据,应立即通过静脉输注进行干预。现在应该考虑铁疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号